



Clonazepam - General Effects

Clonazepam (Klonopin) is a benzodiazepine and central nervous system (CNS) depressant.

1. Clonazepam is prescribed to manage panic disorders, seizure disorders, and as a sedative.
 - a. Clonazepam has a half-life of 19-60 hours.
 - b. Clonazepam has a general therapeutic range, but experienced effects can vary based on an individual's prescription history.
 - i. Therapeutic range refers to the blood concentration expected to achieve the desired therapeutic effects. Due to many factors such as prescription history, dosage, tolerance, drug-drug interactions and use, an individual may exhibit signs of impairment even though blood concentrations fall within the therapeutic range.
2. 7-aminoclonazepam is a major active metabolite of clonazepam.
 - a. Active metabolites can produce impairing effects on the body.
 - b. 7-aminoclonazepam indicates past use of clonazepam.
3. General effects of benzodiazepines include, but are not limited to: drowsiness, sedation, memory impairment, blurred vision, depressed heart rate, incoordination, and respiratory depression.
 - a. General impairing effects of benzodiazepines on driving include but are not limited to: impaired divided attention, inability to maintain lane position, poor coordination, delayed reaction time, difficulty following directions, falling asleep at the wheel, decreased alertness, cognitive impairment, poor perception, confusion, disorientation, and decreased motor skills.
4. The longer an individual uses a drug, the more they can build up a tolerance to its effects. Tolerance occurs when an individual no longer responds to the drug in the way that they initially responded. When an individual gains tolerance to a drug, a higher dose of the drug is necessary to achieve the same level or response initially achieved. As tolerance is gained, it may reduce some of the possible negative effects of a drug.
5. Drug metabolism (alcohol excluded) exhibits first order kinetics, or the elimination of a constant fraction of drug quantity per unit of time, which means that the amount eliminated is proportional to the drug concentration.
6. The use of more than one drug at a time may enhance the effects the drugs would otherwise have on their own, leading to greater impairment.

References

1. Baselt, R.C. (2020). Disposition of toxic drugs and chemicals in man. Biomedical Publications, Seal Beach, CA.
2. Baselt, R.C. (2001). Drug effects on psychomotor performance. Biomedical Publications, Foster City, CA.
3. Moffat, A. C., Osselton, M. D., Widdop, B., & Watts, J. (2011). Clarke's analysis of drugs and poisons (3rd ed., Vol. 1). Pharmaceutical Press.
4. Levine, B., & Vina Spiehler. (2020). Pharmacokinetics and Pharmacodynamics. In B. Levine (Ed.), Principles of Forensic Toxicology (4th ed., pp. 77–93). essay, AACC Press.
5. van Laar, M.W., Volkerts, E.R. (1998). Driving and Benzodiazepine Use. CNS Drugs, vol. 10, no. 5, pp. 383-396.
6. Bramness, J.G., Skurtveit, S., Morland, J. (2003). Testing for Benzodiazepine Inebriation – Relationship between Benzodiazepine Concentration and Simple Clinical Tests for Impairment in a Sample of Drugged Drivers. European of Journal of Clinical Pharmacology, vol. 59, pp. 593-601.
7. Drummer, O.H. (2002). Benzodiazepines – Effects on Human Performance and Behavior. Forensic Sci Rev 14:1.

Template and general factual statements used from Colorado Bureau of Investigation’s monograph system. Edits and fact checking performed by Wisconsin State Crime Laboratory prior to publication.

** The interpretive information provided is not exhaustive nor meant to encompass all scenarios where toxicological results are reported. Interpretive information is meant to serve as a general guide for the reader and that for any given case, consultation with a forensic toxicologist is recommended. **

— Clonazepam Monograph				
Document ID	Revision	Effective Date	Status	Page Number
39034	1	1/18/2023 8:23:00 PM	Published	1 of 1

This controlled document was approved and issued in accordance with the document management provisions established in the Wisconsin State Crime Laboratories Quality System. If viewed outside of Ideagen Quality Management, this is an uncontrolled copy and may no longer be the current revision.